irs program accomplishments · form 990 part iii · fy2024
What they reported doing
- #1 primary $3.31MTHE INSTITUTE FACILITATES MORE EFFICIENT SHARING OF CORE FACILITIES BETWEEN THE THREE PARTNER INSTITUTIONS AND FORMS INDUSTRY PARTNERSHIPS WITH PHARMACEUTICAL AND BIOTECH COMPANIES TO FURTHER ADVANCE DRUG RESEARCH. IT SEEKS TO CREATE INTELLECTUAL PROPERTY THAT CAN BE FURTHER DEVELOPED BY AN OPEN FIELD OF INDUSTRY COLLABORATORS. THE MAJORITY OF SUCH SERVICES RELATE TO MEDICINAL CHEMISTRY SUPPORT.
named programs · 1 · from sources
What they call their work
Medicinal Chemistry Support Program
Provides medicinal chemistry expertise and infrastructure to accelerate drug discovery; facilitates collaboration between academic and industry partners
activities · 1 group
What they do
-
Biomedical Research and Innovation 1 activity
- Facilitate shared use of core research facilities and partner with pharmaceutical and biotech companies to advance drug researchOperates as a collaborative research institute that enables shared access to core research facilities across three partner institutions and forms partnerships with pharmaceutical and biotech companies, primarily providing medicinal chemistry support to accelerate drug discovery and development.
-
financials · form 990 · fy2024
revenue
Total revenue$16.58M
Contributions & grants$330K2%
Program service revenue$16.16M97%
Investment income$87K1%
Other revenue$0
expenses
Total expenses$16.58M
Program expenses93%
Admin / overhead7%
Fundraising0%
Salaries & benefits$7.85M
Grants paid out$0
Largest expense lineCompensation
balance sheet
Total assets$7.31M
Cash$4.83M
Investments$0
Liabilities$7.31M
Net assets$0
Liquid reserves3.5 mo
4 years on record · 2020–2024 · YoY revenue -11.4%
leadership · form 990 part vii · fy2024
Who runs it
paid leadership · 16
| Name | Title | Hours/wk | Compensation |
|---|---|---|---|
| SELWYN VICKERS MD | BOARD MEMBER | 1 | $6.98M |
| ROBERT HARRINGTON MD | BOARD MEMBER | 1 | $2.71M |
| RICHARD P LIFTON MD PHD | BOARD MEMBER | 1 | $1.59M |
| BARBARA HEMPSTEAD MD | BOARD MEMBER | 1 | $861K |
| BARRY COLLER MD | BOARD MEMBER | 1 | $841K |
| DAVID SCHEINBERG MD PHD | BOARD MEMBER | 1 | $758K |
| PETER T MEINKE PHD | SANDERS DIRECTOR | 40 | $696K |
| CARL NATHAN MD | BOARD MEMBER | 1 | $694K |
| NATHANIEL HEINTZ PHD | BOARD MEMBER | 1 | $684K |
| MICHAEL P VITALE | TREASURER | 1 | $594K |
| DEREK TAN PHD | BOARD MEMBER | 1 | $576K |
| MANUEL BACA | VICE PRESIDENT, BIOLOGICS | 40 | $475K |
| PATRICIA AHA | VICE PRESIDENT, OPRATIONS | 40 | $361K |
| NIGEL LIVERTON PHD | VICE PRESIDENT, CHEMISTRY | 40 | $351K |
| PAUL BALDERES | SR. DIRECTOR | 40 | $342K |
| SANDRA LORBER | VICE PRESIDENT, FINANCE | 40 | $302K |
relationships · 3
Who they work with
- Rockefeller University Partner — Tri-institutional partner in therapeutics discovery research
- Sloan Kettering Institute Partner — Tri-institutional partner in therapeutics discovery research
- Weill Cornell Medicine Partner — Tri-institutional partner in therapeutics discovery research
strategies · 1
How they approach the work
Named approaches extracted from this org’s sources. Where others share an approach, follow it to see the full set of orgs running it.